The Administrative Core is comprised of Cancer Center Administration and Senior Leadership. Abramson Cancer Center (ACC) Administration provides centralized coordination of resources and services required to facilitate the ACC's scientific mission to reduce the burden of cancer. Coordinated activities include: participation in the governance and decision-making processes of the Center; representation of the Center within the parent Institution; and the oversight and management of multiple CCSG-related activities. CCSG- relevant activities include: support of Planning and Evaluation; oversight of Shared Resources; support of faculty recruitment; management of the membership process and data, such as publications and grants; management of the Pilot Projects Program; space management; coordination and documentation of Center meetings; budgeting and financial management; and management of the CCSG application. ACC Administration is comprised of a cohesive group of highly experienced staff with the demonstrated expertise needed to enable the ACC to realize its mission and respond to the growing research needs of the membership. These key administrative staff members have clearly defined roles, responsibilities and reporting lines, ensuring that the administrative activities of the ACC are delivered in an effective and efficient manner. ACC Administration provides vital support to the ACC Director, Senior Leadership, Program Leaders, Advisory Groups, Shared Resources and members. Senior Leadership is a carefully selected group of nationally prominent individuals who have clearly defined roles while sharing overall responsibility for realizing the mission of the ACC, developing and implementing strategies that respond to the needs of members, and fostering a creative, cohesive cancer research environment that encourages transdisciplinary team science across the translational pipeline. Leaders identify scientific issues and strategic priorities and review progress toward achieving goals. Dr. Chi Dang has served as Director since 2011, replacing Dr. Craig Thompson. Dr. Caryn Lerman has continued in her role as Deputy Director, as have Dr. Lewis Chodosh as AD for Basic Research, Dr. Garrett Brodeur as AD for Pediatric Research, Dr. Timothy Rebbeck as AD for Population Science, and Dr. James Alwine as AD for Shared Resources. Dr. Roger Cohen replaced Dr. Lynn Schuchter as AD for Clinical Research. Three new AD positions were created: Dr. Robert Vonderheide was appointed AD for Translational Research, Dr. Carmen Guerra was appointed AD for Diversity and Outreach, and Dr. Brian Keith was appointed AD for Education and Training. Mr. Robert Wynne was promoted from AD for Finance to AD for Administration.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016520-40
Application #
8998396
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2015-12-01
Budget End
2016-11-30
Support Year
40
Fiscal Year
2016
Total Cost
$714,368
Indirect Cost
$267,888
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Micallef, Ivana N; Stiff, Patrick J; Nademanee, Auayporn P et al. (2018) Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. Biol Blood Marrow Transplant 24:1187-1195
Nicastri, Michael C; Rebecca, Vito W; Amaravadi, Ravi K et al. (2018) Dimeric quinacrines as chemical tools to identify PPT1, a new regulator of autophagy in cancer cells. Mol Cell Oncol 5:e1395504
Medvec, Andrew R; Ecker, Christopher; Kong, Hong et al. (2018) Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium. Mol Ther Methods Clin Dev 8:65-74
Acosta, Jonuelle; Wang, Walter; Feldser, David M (2018) Off and back-on again: a tumor suppressor's tale. Oncogene 37:3058-3069
Crisalli, Lisa M; Hinkle, Joanne T; Walling, Christopher C et al. (2018) Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. Biol Blood Marrow Transplant 24:1203-1208
Mazaleuskaya, Liudmila L; Salamatipour, Ashkan; Sarantopoulou, Dimitra et al. (2018) Analysis of HETEs in human whole blood by chiral UHPLC-ECAPCI/HRMS. J Lipid Res 59:564-575
Facompre, Nicole D; Harmeyer, Kayla M; Sahu, Varun et al. (2018) Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer. Oncotarget 9:8985-8998
Rosenfeld, Aaron M; Meng, Wenzhao; Chen, Dora Y et al. (2018) Computational Evaluation of B-Cell Clone Sizes in Bulk Populations. Front Immunol 9:1472
Shroff, Rachna T; Hendifar, Andrew; McWilliams, Robert R et al. (2018) Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precis Oncol 2018:
Fraietta, Joseph A; Lacey, Simon F; Orlando, Elena J et al. (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:563-571

Showing the most recent 10 out of 1047 publications